Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2023 10:47 ET | Source: Nkarta, Inc.

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose in the Phase 1 dose escalation...
May 11, 2023 16:02 ET | Source: Nkarta, Inc.

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023Cash and cash equivalents of $332.1 million on March 31, 2023Cash runway...
May 11, 2023 16:01 ET | Source: Nkarta, Inc.

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that...
April 17, 2023 17:01 ET | Source: Nkarta, Inc.

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

Improved ADCC with ADAM17 gene knockout of NK or CAR NK cells, supporting ADAM17 KO use for clinical applications Increased specific killing of cancer cells in vitro by the combination of NKX101 and...
April 12, 2023 21:06 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
March 30, 2023 16:01 ET | Source: Nkarta, Inc.

Nkarta Announces Departure of Chief Financial & Business Officer

Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage...
March 16, 2023 16:01 ET | Source: Nkarta, Inc.

Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 20232022 year-end cash and cash equivalents of $354.9 millionCash runway anticipated to fund operations into 2025 ...
February 09, 2023 08:02 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
January 09, 2023 16:30 ET | Source: Nkarta, Inc.

Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
December 05, 2022 07:02 ET | Source: Nkarta, Inc.

Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)5 CRs achieved across all dose levels after a single cycle...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right